Last reviewed · How we verify
TSA-CTL
At a glance
| Generic name | TSA-CTL |
|---|---|
| Also known as | Tumor Specific Antigen Induced Cytotoxic Lymphocyte |
| Sponsor | BGI, China |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
- Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSA-CTL CI brief — competitive landscape report
- TSA-CTL updates RSS · CI watch RSS
- BGI, China portfolio CI